SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : genelabs(gnlb)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jjs64 who wrote (116)2/12/1998 2:40:00 PM
From: biotech  Read Replies (1) of 233
 
The conference call was very positive with many investors very impressed with the deal GNLB signed with DARPA. It is well recognized that DARPA is one of the most thorough investigators of technology in the world.

1) The Dupont/Merck collaboration is going extremely well and I believe they will receive a significant milestone payment in the near future.

2)The sister technology to MERLIN, VIRIA, is not part of the Dupont/Merck collaboration.

3) The Lupus enrollment for the second phase III trial is ahead of schedule.

4) Comparing the valuation of GNLB to other genome companies the shares are very undervalued. For example, HGSI has a market cap of over $950 mm, INCY over $1.1 billion and GNLB at only $150mm.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News